Autopsy report · NCT00147238

A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Terminated at request of sponsor.”

The sponsor’s own words in the registry.

Life of this trial

Registered 2 months after it had already started.
Ran for about 1 year 6 months before it stopped.
10 participants enrolled.
Results were posted on the registry 3 years after it ended.

Vital statistics

Status: Terminated
Phase: Na
Sponsor: M.D. Anderson Cancer Center
Sponsor type: University, hospital or other
Conditions: Bladder Cancer; Genitourinary Cancer; Prostate Cancer
Interventions: Ferumoxtran-10 (USPIO); MR lymphangiography
Participants: 10
Sites: 1
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.